Survival impact and risk factors of skeletal muscle loss during first-line EGFR-TKIs therapy in advanced lung adenocarcinoma patients.

ABSTRACT:

Purpose

The impact of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) on muscle mass in individuals with advanced lung cancer has yet to be fully delineated. This study aimed to examine the dynamics of skeletal muscle mass during EGFR-TKIs targeted therapy, elucidate its clinical relevance, and explore the potential mechanisms.

Methods

We retrospectively recruited 104 patients with EGFR-mutant advanced lung adenocarcinoma who received icotinib or afatinib as first-line treatment. Skeletal muscle changes were assessed by abdominal CT obtained before and during treatment with EGFR-TKIs. The mean interval (± SD) between two CT scans was 109 days (± 16 days). Targeted panel sequencing of tumor tissue was used to detect genetic alterations. Functional en

SUBMITTER: Nie X 

PROVIDER: S-EPMC11881361 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature